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Long-term engraftment and phenotype correction has been difficult to achieve in humans after in utero stem
cell transplantation mainly because of allogeneic rejection. Autologous cells could be obtained during gesta-
tion from the amniotic fluid with minimal risk for the fetus and the mother. Using a sheep model, we
explored the possibility of using amniotic fluid mesenchymal stem cells (AFMSCs) for autologous in utero
stem cell/gene therapy. We collected amniotic fluid (AF) under ultrasound-guided amniocentesis in early
gestation pregnant sheep (n = 9, 58 days of gestation, term = 145 days). AFMSCs were isolated and ex-
panded in all sampled fetal sheep. Those cells were transduced using an HIV vector encoding enhanced
green fluorescent protein (GFP) with 63.2% (range 38.3–96.2%) transduction efficiency rate. After expan-
sion, transduced AFMSCs were injected into the peritoneal cavity of each donor fetal sheep at 76 days under
ultrasound guidance. One ewe miscarried twin fetuses after amniocentesis. Intraperitoneal injection was
successful in the remaining 7 fetal sheep giving a 78% survival for the full procedure. Tissues were sampled
at postmortem examination 2 weeks later. PCR analysis detected GFP-positive cells in fetal tissues including
liver, heart, placenta, membrane, umbilical cord, adrenal gland, and muscle. GFP protein was detected in
these tissues by Western blotting and further confirmed by cytofluorimetric and immunofluorescence analy-
ses. This is the first demonstration of autologous stem cell transplantation in the fetus using AFMSCs.
Autologous cells derived from AF showed widespread organ migration and could offer an alternative way
to ameliorate prenatal congenital disease.
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INTRODUCTION treat congenital disorders in the fetus using cells capable
of self-renewal that can enhance or substitute the af-
fected tissues/organs of the fetus. The small fetal sizeMany congenital diseases have a relatively low prev-
alence, but collectively they represent a large burden of provides a stoichiometric advantage, allowing the trans-
plantation of much larger cell doses on a per kilogramdisease (28). It is estimated that they are responsible for
over a third of all pediatric hospital admissions, and for basis than can be achieved after birth (4,7). Prenatal
treatment could also avoid complications occurring inup to 50% of the total cost of pediatric hospital treat-
ment (28). Due to the improvement in medical care, af- the postnatal period, as some genetic diseases damage
the organ in utero and lead to irreversible changes (10).fected patients can now survive to adulthood, requiring
continued therapy. Finally, the immunological naivety in the early gestation
fetus has given rise to the concept of fetal tolerance,In utero stem cell transplantation (IUSCT) aims to
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the inability to raise an immunological response against MATERIALS AND METHODS
foreign antigens (21). However, it is now clear that the Animal Procedures
human fetus may have a functionally developed immune
Nine fetuses from seven ewes (Romney breed) were
system as early as the second trimester of gestation (49)
used in these experiments. The experimental design is
and allogeneic cells injected at that time engraft poorly
illustrated in Figure 1A. Ewes were time mated after(30,35). In humans, successful IUSCT using allogeneic
receiving intravaginal progesterone suppositories for 2hematopoietic stem cells (HSCs) has been limited to fe-
weeks to induce ovulation. General anesthesia was in-tuses with severe immunologic defects, where the effec-
duced with ketamine (4 mg/kg, Merial, UK) intrave-tive lack of immune response to allogeneic cells mean
nously and, after intubation, the ewes were maintainedthat transplanted genetically normal cells have a prolif-
on isoflurane-Vet 3% (Merial, UK) in oxygen. Fetal
erative advantage (46).
measurements were confirmed by ultrasound as pre-Mesenchymal stem cells (MSCs) appear to be less
viously described (11). The first procedure, amniocente-immunogenic than their hematopoietic counterparts (2,
sis (Fig. 1B), was performed in early pregnancy (57–6134). IUSCT of first trimester human fetal blood MSCs
days of gestation, term = 145 days) under ultrasoundin mice with osteogenesis imperfecta (OI) was reported
guidance using a 22-gauge, 15-cm echo-tip needleto ameliorate skeletal pathology (23). In a human fetus (Cook Medical, USA) and 10 ml of amniotic fluid was
affected by OI successful engraftment of allogeneic
withdrawn from each amniotic sac. After recovery fetalMSCs with 5% chimerism was obtained at 8 months of
well-being was confirmed using ultrasound examination.
age (27). In normal fetal sheep, where the immune sys-
Approximately 2 weeks later (71–83 days of gesta-tem is believed to develop from 65 to 70 days of gesta-
tion) sheep were reanesthetized as above for the secondtion (29), transplantation of allogeneic fetal liver cells
procedure. Transduced AFMSCs (1–2 ml) were injected
resulted in levels of mixed chimerism as high as 30%
under ultrasound guidance into the peritoneal cavity of
after a single intrauterine dose (19,54,55) and low-level
the fetus from which they were derived (Fig. 1C) using
engraftment lasted for over 2 years. Increasing the num-
a 20-gauge 15-cm echo-tip disposable needle (Cookbers of T-cells added back to the transplant increased
Medical). To ensure correct needle placement within thethe level of chimerism, although the corresponding in-
peritoneal cavity, the needle was inserted through the
creased risk of graft-versus-host disease limits the num-
anterior abdominal wall of the fetal sheep superior andber of allogeneic cells that can be transplanted (6,8). At-
lateral to the fetal bladder to avoid the umbilical arteries,tempts to treat other diseases such as sickle cell or
and microbubbles were observed moving within the
metabolic storage disorders have been unsuccessful,
peritoneal cavity as the vector was instilled. Fetal well-
even where a suitably matched donor has been available
being was examined after the procedure. A scheduled(14,51).
postmortem examination was performed approximatelyAutologous cells could potentially overcome these
3 weeks after intraperitoneal AFMSC transplantation
obstacles (1,35,38,43,53). Multi- and pluripotent stem (89–103 days of gestation). There was widespread sam-
cells can be easily derived from amniotic fluid (5,15)
pling of maternal and fetal tissues that were fixed in 4%
and their ability to differentiate into various lineages
paraformaldehyde (pH 7.4) overnight and processed into
such as myogenic, adipogenic, osteogenic, neuronal, en-
wax for immunohistochemistry analysis. In parallel, tis-dothelial, and hepatic cells has been extensively investi-
sues were also snap-frozen for protein extraction andgated (15,16,24–26,48). Moreover, we and others have
PCR analysis. Cord blood, spleen, liver, and bone mar-demonstrated that amniotic fluid-derived stem cells can
row of fetal sheep and maternal peripheral blood andbe easily transduced without losing their potential (16,
bone marrow were collected for FACS flow cytometry.22). Therefore, transplantation of genetically corrected
All procedures on animals were conducted in accor-
autologous amniotic fluid stem cells into a fetus could
dance with UK Home Office regulations and Guidance
represent an alternative therapeutic strategy for the treat-
for the Operation of Animals (Scientific Procedures) Act
ment of severe congenital diseases. (1986).In this study, we investigated the feasibility and
potential for amniotic fluid mesenchymal stem cells
Ex Vivo Expansion of Amniotic Fluid Mesenchymal(AFMSCs) in order to combine IUSCT and gene therapy
Stem Cellsinto one therapeutic strategy. With this aim we used the
fetal sheep, which has the advantages of long gestational Amniotic fluid samples collected from fetal sheep
were centrifuged (300 × g) for 5 min. Pellets were resus-age, similar fetal size, and comparable fetal development
and physiology to human pregnancy (10,13) and in pended in the amniotic culture medium (ACM), which
consisted of αMEM (63%, Life Technology, Gaithers-which there is wide experience with fetal interventional
procedures (9,12). burg, MD), Chang medium (20%, Chang B plus Chang
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Figure 1. Experimental design and injection procedure. After amniocentesis collection, amniotic
fluid mesenchymal stem cells (AFMSCs) were cultured in adherence in defined conditions (A).
Cells were transfected with lentivirus GFP and reinjected into the peritoneal cavity of the fetal
donor. Sonograms showing ultrasound guided amniocentesis (B) and intraperitoneal injection (C).
Amniocentesis was performed using a 22-gauge needle to collect 10 ml amniotic fluid from the
amniotic cavity around a fetal sheep at 58 days of gestation. For intraperitoneal injection of trans-
duced expanded amniotic fluid cells we used a 20-gauge needle inserted through the anterior
abdominal wall of a sheep fetus at 76 days of gestation. Echogenicity can be seen throughout the
peritoneal cavity after injection of cells. Scale bars: 5 cm. (D) The timeline of the experiment.
C; Irvine Scientific, Santa Ana, CA), fetal bovine serum changing new medium and the adherent cells were cul-
tured until preconfluence. Adherent cells were detached(FBS, 15%, Invitrogen, UK), and streptomycin, penicil-
lin, and L-glutamine (1% each, Invitrogen). Cell seeding from the plastic substrate using 0.05% trypsin and
0.02% sodium-EDTA (Life Tech). Cells were passagedwas performed on single 35-mm Falcon petri dishes
(Becton Dickinson, Los Angeles, CA) that incubated at into 100-mm petri dishes and further split one to four
once the dish reached 70% confluence. Cell size and37°C with 95% air and 5% carbon dioxide. After 3 days,
nonadherent cells and debris were discharged while number was determined using a hemocytometer (Ma-
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rienfeld, Germany) before and after viral transduction. phatase kit was used for osteogenic cells staining
according to the manufacturer’s instruction (Sigma-The formula used for the doubling time (hours) was
h*log(2)/log(c2/c1), where c1 is initial seeding cell Aldrich). ACM was used as a control growth medium
in control conditions.number, c2 is cell number after growth, and h is hours
of culture. Lentiviral Vectors Preparation and Transduction
of Sheep Amniotic Fluid Stem CellsCell Cycle Analysis
A lentivirus vector encoding the the HIV-1 centralPropidium iodine (PI) was used to stain cell nucleic
polypurine tract element, the Spleen Focus Forming Vi-acid to identify the proportion of cells that are in one of
rus LTR promoter, and the marker gene eGFP was used.the three interphase stages of the cell cycle. Briefly, 1 ×
Vector stocks were generated as previously described106 AFMSCs were washed in PBS and centrifuged to (17,39), and were concentrated by ultracentrifugation atproduce a cell pellet. Seventy percent ethanol (1 ml) was
23,000 × g for 2 h at 4°C using a Beckmann ultracentri-added to fix the cell pellet during centrifugation. After
fuge. The virus particles were resuspended in X-Vivo 1030-min incubation on ice, cells were pelleted using a
and stored at −80°C. The number of infectious particleshigh-speed centrifuge at 3000 rpm for 5 min. Ribo-
was estimated by flow cytometry of 293T cells, 72 hnuclease A solution (50 µl, 100 µg/ml) and PI solution
after exposure to serial dilutions of virus stock. Cells(400 µl, 50 µg/ml) were added directly into the PBS
cultured in ACM (1 × 106) and were seeded into 24-wellwashed pellet for 10 min at room temperature. The sam-
non-tissue culture dishes. After 24 h they were trans-ples were analyzed by flow cytometry as described
duced with the lentivirus vector at a multiplicity of in-below.
fection of 10 virus particles per cell. Cells were incu-
bated with the vector for 48 h at 37°C in 95% air andDifferentiation and Characterization of Amniotic Fluid
5% carbon dioxide. Transduced cells were treated withMesenchymal Stem Cells
trypsin and replated into 100-mm dishes for furtherIn order to characterize the isolated, cultured, and
growth in ACM.transduced amniotic fluid cells, the following surface
markers were used. Mouse anti-sheep CD14, CD31, Flow Cytometry Analysis
CD44, CD45, and CD58 antibodies conjugated with flu- Single cell suspensions of fetal spleen, liver, and
orescein isothiocyanate (FITC) (AbD Serotec, UK), and bone marrow were prepared immediately after animal
mouse anti-human CD166 conjugated with phycoery- sacrifice by straining fetal tissue through a 40-µm nylon
thrin (PE) (BD Pharmingen, UK) were used for charac- mesh cell strainer (BD, UK). The fetal tissue was passed
terization of the nontransduced AFMSCs. Goat anti-mouse through the cell strainer with PBS rinsing. After washing
Alexa Fluor 568 (Invitrogen) was used as secondary with PBS, red blood cell lysis buffer was added to the
antibody to mouse CD14, CD31, CD44, CD45, and cell pellet for 5 min at 37°C, which was then resus-
CD58 in order to identify the GFP-transduced AFMSC pended in PBS for flow cytometry analysis. Mononu-
cells. Antibodies (10 µl) were stained with 5 × 105 cells clear cells were isolated from umbilical cord and mater-
in 100 µl ice-cold PBS. The incubation time was 15 min. nal blood samples by density gradient centrifugation
The stained cells were analyzed with flow cytometry. using Ficoll-Paque solution (Stem Cell Technology,
To induce adipogenic differentiation, cells from pas- Canada). Diluted blood solution (10 ml of blood and 25
sage 2 were seeded at a density of 3,000 cells/cm2 and ml of buffer) was centrifuged with Ficoll solution (15
were cultured for 21 days in DMEM low-glucose me- ml) 30 min at 2000 rpm at room temperature without
dium with 10% FBS, antibiotics (Pen/Strep, Gibco/ breaking to form the interphase. Then the interphase was
BRL), and adipogenic supplements [1 mM dexametha- carefully transferred to another new tube for further
sone, 1 mM 3-isobutyl-1-methylxanthine, 10 mg/ml in- analysis. Single cell suspensions from control untrans-
sulin, 60 mM indomethacin (Sigma-Aldrich, UK)]. The fected ewes and their fetuses were used as negative con-
cells were stained with Oil red O (Sigma-Aldrich). ACM trols. The cells were acquired by Becton Dickinson
was used as a control growth medium in control condi- FACSCalibur and LSR II machines (Becton Dickinson,
tions. San Jose, CA) and analyzed using FlowJo version 5.7.1
For osteogenic differentiation, cells from passage 2 software (Tree Star). Ten thousand events were col-
were seeded at a density of 3,000 cells/cm2 and were lected per sample and the data were stored as list mode
cultured for 21 days in DMEM low-glucose medium files.
with 10% FBS (Gibco/BRL), Pen/Strep, and osteogenic
PCR Analysissupplements [100 nM dexamethasone, 10 mM betaglyc-
erophosphate (Sigma-Aldrich), 0.05 mM ascorbic acid- DNA was extracted from fetal and maternal tissues
using a minikit (Invitrogen, USA) and the quality was2-phosphate (Wako Chemicals, UK)]. An alkaline phos-
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confirmed using a nanodrop machine (NanoDrop Tech- primary antibodes were applied. Secondary goat anti-
rabbit (Alexa Fluor 594) and goat anti-mouse (Alexanologies, USA). Sample DNA (4 µg) was used for the
first PCR reaction (30 cycles of 45 s at 65°C). The fol- Fluor 488) antibodies were used. The conditions for pri-
mary and secondary antibody staining were the same aslowing primers were used for first round amplification
of eGFP: forward, 5′-TGAACCGCATCGAGCTGAA for hepatocyte analysis. The stained tissues were cov-
ered by VECTASHIELD HardSet Mounting MediumGGG-3′ and reverse, 5′-TCCAGCAGGACCATGTGA
TCGC-3′. A second nested PCR round was performed with DAPI for nuclear staining (Vector Laboratories,
USA). The slides were observed under inverted immu-(25 cycles of 45 s at 60°C) using the following second
round primers: forward, 5′-GGCACAAGCTGGAGTA nofluorescence microscopy (Leica, Germany). In order
to quantify the number of AFMSCs migrated in the fetalCAACT-3′ and reverse, 5′-CCATGTGATCGCGCTT
CT-3′. PCR products were analyzed on 1.2% agarose liver, we counted GFP and CK18 positive/negative
stained cells in four high-power fields per fetal liver.gel stained with ethidium bromide. DNA from trans-
duced amniotic fluid cells was used as a positive control. Values (mean ± SD) were expressed as the percentage
of single- or double-positive stained cells per total nuclei
Western Blot Analysis in each high power field.
Cell pellets and homogenized tissues were resus-
pended in 200 µl PBS and 200 µl 2× protein sample RESULTS
buffer [0.5 M Tris-HCl (pH 6.8), 5% glycerol, 2% so- Ultrasound Guided Amniocentesis and Intraperitoneal
dium dodecyl sulfate, and 100 mM dithiothreitol]. Sam- Injection of AFMSCs
ples were boiled for 5 min and centrifuged at 16,000 ×
Amniotic fluid was successfully sampled in all nineg for 15 min to remove insoluble material. Samples were
fetuses. One ewe subsequently miscarried twin fetalloaded onto a precast 7.5% Ready gel with a 4.5%
sheep a few days after the amniocentesis procedures, butstacker (BioRad Laboratories, Hercules, CA) and run for
before intraperitoneal injection could be performed. In-1 h at 200 V. After electrophoresis, proteins were trans-
traperitoneal injection (n = 7) was successfully per-ferred to nitrocellulose membranes in a Bio-Rad Elec-
formed with no fetal or maternal mortality until plannedtroblotter Apparatus. Membranes were blocked in TBST
postmortem examination in the remaining seven fetal(TBS, 0.05% Tween 20, Sigma, UK) containing 5%
sheep, giving a 78% survival for the full procedure. Ex-milk for 1 h at room temperature and then reacted over-
perimental details are listed in Table 1. There was nonight at 4°C with rabbit anti-GFP (Invitrogen, USA) di-
maternal morbidity including fever, abdominal disten-luted 1:2000 in TBST-milk. After three washes in TBST,
sion, hemorrhage, or ruptured amniotic membranes.the membranes were treated with affinity-purified horse-
There was no evidence of fetal hemorrhage or traumaradish peroxidase-conjugated goat anti-rabbit IgG (Pro-
relative to the injection procedure.mega, Madison, WI, USA) diluted 1:4000. Membranes
were washed three times in TBST, and then developed
Sheep AFMSC Isolation, Expansion, and Characterizationwith a 3,3′-diaminobenzidine-based horseradish peroxi-
dase detection kit (Vector Laboratories, USA). AFMSCs could be isolated and expanded in vitro
from all the nine sheep (100%). The initial numbers of
Immunofluorescence viable cells from 10 ml amniotic fluid in all animals
were less than 20,000 cells, but they were easy to ex-Fresh fetal tissues were embedded in OCT, snap fro-
zen in methyl-butane and liquid nitrogen, and cut into pand in petri dishes without feeder layer and demon-
strated a doubling time ranging from 36 to 48 h (Fig.10–15-µm sections using a cryostat (OTF, Bright, UK).
Blocking solution was prepared with 1% BSA, 0.15% 2A). AFMSC growth velocity and differentiation poten-
tial was maintained for up to 10 passages (Fig. 2A). Inglycine, and 0.1% Triton in PBS and preserved at 4°C.
To co-stain hepatocytes expressing GFP, mouse anti- order to achieve a sufficient number of cells for trans-
plantation, cells were cultured for up to 20 passages.sheep CK18 (Abcam, UK), mouse anti-sheep α-feto-
protein antibody-2 (AFP) (Thermo Scientific, UK), and The number of injected cells was correlated with the
time available for their culture from amniocentesis torabbit anti-GFP polyclonal (Invitrogen, USA) primary
antibodies were applied at 1:150 concentration in block- transplantation (time of cell culture and transduction in
days in Table 1). Subconfluent cells also showed no evi-ing solution overnight at 4°C. Goat anti-rabbit (Alexa
Fluor 488, Invitrogen, USA) and goat anti-mouse (Alexa dence of spontaneous differentiation (data not shown).
The cell size and DNA content from cell cycle analysisFluor 568) secondary antibodies were incubated for 2
h at room temperature with blocking solution at 1:150 did not show a significant difference between pre- and
posttransduction AFMSCs (Fig. 2B, C). Samples ofconcentration. To co-stain myocytes expressing GFP,
rabbit anti-laminin (Abcam, UK) and mouse anti-GFP AFMSCs and GFP-AFMSCs had higher ratio in G0/G1
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Table 1. Experimental Details
Gestational Age (Days) Times (Days)
AFMSC
Amnio- Transplan- Post- Cell Culture Cell Cells Injected Cell Transduction
Sheep centesis tation mortem and Transduction Migration Injected Volume (ml) Efficiency (%)
1 55 71 89 16 18 1 × 105 1 nt
2 58 76 99 18 23 1.6 × 106 1 64.2
3 59 77 95 18 18 7 × 106 1 53
4 59 77 95 18 18 1.8 × 107 2 38.3
5 57 79 99 22 20 9 × 106 1.5 96.2
6 61 83 103 22 20 1.5 × 107 2 62.3
7 59 72 91 13 19 2 × 106 1.5 65.1
Average ± SD 58.3 ± 1.9 76.4 ± 4.1 95.9 ± 4.9 7.5 × 106 1.4 × 0.4 63.2 × 19.1
After sampling of amniotic fluid (amniocentesis), cells were cultured and transduced in vitro, before being injected into the peritoneal cavity of the
donor fetus (transplantation). Scheduled postmortem examination was performed approximately 3 weeks later to allow time for cell migration. nt:
not tested.
phase, with low percentage of S phase and G2/M phase ent organs as analyzed by PCR or Western blot [r =
−0.18 (Fig. 5B) and r = −0.4 (Fig. 5C)]. Maternal liver,(Fig. 2C).
The surface markers of mesenchymal stem cells, anti- bone marrow, kidney, lung, heart, and adrenal gland
were examined using GFP nested PCR but were nega-sheep CD44, CD58, and CD166, were strongly positive
in cultured sheep AF cells. The monocyte and lympho- tive, indicating no evidence of maternal engraftment
after fetal transplantation (Fig. 5D).cyte markers, anti-sheep CD14, CD31, and CD45, showed
negative in sheep cells (Fig. 2D). The results are the
Analysis of GFP Protein Expression in Fetal Organssame either in the pre- or posttransduced AFMSCs. The
two groups of cells that could be expanded in vitro Cytofluorimetric analysis showed low-level presence
of transduced AFMSCs in fetal bone marrow (0.85 ±showed the ability to differentiate into adipogenic and
osteogenic lineages following the differentiation proto- 0.13%) and liver (1.24 ± 0.08%). Figure 6 shows one of
the animals with positive stainin in bone marrow andcols (Fig. 3).
liver. There were no GFP-positive cells in fetal umbili-
AFMSCs Transduction With Lentivirus GFP Vector cal cord blood and spleen, or maternal blood and bone
marrow. GFP protein expression was also assessed byTransduction efficiency, assessed 3 days after lentivi-
ral transduction using cytofluorimetric analysis, was on Western blot in those fetal tissues in which GFP DNA
was detected (Table 2). There was insufficient proteinaverage 63.2% (range 38.3–96.2%) (Fig. 4A, B, Table
1). GFP expression was also detected when AFMSCs available in samples of fetal gonad and peritoneum for
Western blot analysis. The most frequent tissues to havewere observed under fluorescence microscopy (Fig. 4C).
Cell kinetics of GFP transduced AFMSCs was similar positive GFP protein expression were the placenta (6/7,
86%), the fetal liver, and the amniotic membranes (5/7to nontransduced AFMSCs (Fig. 2A).
fetuses, 71%, Table 2). Of all tissue samples that were
Detection of GFP DNA in Fetal and Maternal Organs PCR positive for GFP, Western blot confirmed GFP pro-
tein in 77.8% (21/27) of them. The presence of GFPGFP DNA was detected in many fetal organs using
nested PCR, suggesting systemic spread of GFP-positive protein detected 3 weeks after injection of transduced
AFMSCs was strong evidence of cell migration in thesecells after fetal injection (Table 2). The amniotic mem-
brane and placentomes were most frequently positive tissues after transplantation.
Finally, to confirm the presence of GFP-positive(85.7%), followed by the fetal liver, which was positive
in five fetuses (71.4%). GFP DNA was also detected in AFMSCs in fetal tissue, we used immunofluorescence
to analyze selective organs including fetal liver, skeletalfetal muscle, umbilical cord, heart, adrenal gland, gonad,
bone marrow, and peritoneum. The cell number we in- and cardiac muscle, and placenta. For hepatocyte differ-
entiation, we analyzed expression of GFP, cytokeratinjected in each animal was varied. The length of cell cul-
turing and final cell number for injection showed moder- 18 (CK18), and AFP in the liver of the four fetuses that
had GFP-positive staining. Two liver lobes were exam-ate correlation (r = 0.59) (Fig. 5A). There was no
significant correlation between the number of injected ined in each fetus. In some sections, GFP-positive cells
did not co-stain with CK18 (Fig. 7A–D). Only a fewcells and the presence of GFP-positive cells in the differ-
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Figure 2. Characterization of sheep amniotic fluid mesenchymal stem cells. The growth curve (A) demonstrates that the doubling
time of both AFMSCs and GFP-FAMSCs was around 36–48 h (error bar: SD). (B) The cell size from AFMSCs and GFP-AFMSCs,
which did not present statistical significance. (C) The DNA content of cells cycle by using flow cytometry analysis. The cell cycle
did not showed significant difference between AFMSCs and GFP-AFMSCs. (D) The sheep AF cells stained strongly positive for
MSC surface markers CD44, CD58, and CD166, confirming their mesenchymal origin. Anti-sheep CD14, CD31, and CD45 were
negative compared to background staining (light gray, negative control; dark gray, anti-sheep antibodies).
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Figure 3. Differentiation potential of sheep amniotic fluid mesenchymal stem cells. Adipogenesis differentiation showing lipid
drops with positive staining of Oil red O (A and insets) present in AFMSCs and GFP-AFMSCs. Moreover, both groups of cells
could undergo osteogenic differentiation (B), expressed alkaline phosphatase, and formed lamellar-like structures (insets). Both
AFMSCs and GFP-AFMSCs cultured in control conditions did not show adipogenic (A) and osteogenic differentiation (B). Scale
bars: 20 µm.
GFP-positive cells presented in animals were seen co- AFMSCs in the liver after autologous transplantation
(Fig. 8B).stained with CK18-positive cells in both liver lobes, sug-
gestive of hepatocyte differentiation (Fig. 7E–G). More-
DISCUSSIONover, the percentages of positive cells per slide were
2.97 ± 1.15% for GFP+/CK18− cells and 1.08 ± 0.33% This is the first study to describe in utero autologous
transplantation and migration of AFMSCs. We showedfor GFP+/CK18+ cells in the fetal liver (Fig. 7H). For
muscle differentiation, we analyzed the expression of that using this system, it is possible to obtain a wide-
spread migration of transduced autologous cells, withGFP and laminin. GFP-positive cells were clearly de-
tected in the skeletal muscle (Fig. 7I) and heart (Fig. 7J) evidence of expression of transgenic protein in major
fetal organs, bone marrow, and blood. Tissue analysisof four fetuses. No myogenic differentiation could be
observed when muscles were co-stained with laminin. by PCR, Western blot, immunofluorescence, and cy-
tofluorimetric assay revealed that AFMSCs injected intoAbundant GFP-positive cells could be detected in pla-
centome (Fig. 7K–M). the peritoneal cavity preferentially localized in fetal
liver, muscle, and heart. Moreover, a small number ofBoth AFMSCs and GFP-AFMSCs did not show
CK18 expression from our study, while the noninjected cells expressing transgenic protein in the liver co-stained
with markers of hepatocyte differentiation.fetal sheep as a positive control showed strong expres-
sion of CK18 in the liver (Fig. 8A). AFP, another liver- Using ultrasound-guided amniocentesis, a common
clinical procedure with a known fetal loss rate of ap-specific marker, also demonstrated the presence of GFP-
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Figure 4. Transduction efficiency of AFMSCs. After transduction with lentivirus vector, AFMSCs were analyzed at the cytofluori-
meter for GFP expression to determine the efficiency of gene transfer. For fetus 6, posttransduction cells in the GFP channel can
be seen with 62.3% cells expressing GFP (B); the negative control is indicated (A). Cells were gated on the basis of the region
shown on the forward (FSC-A) and side (SSC-A) scatter dot plot (left); the percentage of donor cells calculated by selection of the
high fluorescence population on the cell count versus fluorescence intensity (GFP-A) histogram (right). AFMSCs were observed in
bright field (C, left panel) and under a fluorescent microscope where the positive GFP expression could be detected within the
cytoplasm of each AFMSC (C, right panel). Scale bars: 20 µm.
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Fetal Tissue 1 2 3 4 5 6 7 in Organ (%)
PCR analysis of GFP DNA
Liver + − + + + − + 5 (71%)
Muscle (thigh) + − − − + − − 2 (29%)
Amniotic membranes + + + + + + − 6 (86%)
Placentome − + + + + + + 6 (86%)
Umbilical cord + − − + − − − 2 (29%)
Heart + − + − + − − 3 (43%)
Adrenal gland + − − − + + − 3 (43%)
Gonad − − + + − − − 2 (29%)
Bone marrow + − − − − − + 2 (29%)
Amniotic fluid cells − + + + − − + 4 (57%)
Peritoneum − + − − + − + 3 (43%)
Brain − − − − − − − 0
Spleen − − − − − − − 0
Intestine − − − − − − − 0
Thyroid − − − − − − − 0
Thymus − − − − − − − 0
Lung − − − − − − − 0
Kidney − − − − − − − 0
No. of organs detected per
animal (total = 18) 7 (39%) 4 (22%) 6 (33%) 6 (33%) 7 (39%) 3 (17%) 5 (28%)
Western blot analysis of GFP protein
Liver + − + + + − + 5 (71%)
Muscle (thigh) + − − − + − + 3 (43%)
Amniotic membranes + + + − + + − 5 (71%)
Placentome + + + − + + + 6 (86%)
Umbilical cord + − + + − − + 4 (57%)
Heart − − + − + − − 2 (29%)
Adrenal − − − − − + − 1 (14%)
proximately 1% (45), we were able to isolate AFMSCs ilar to that we have previously reported for both intra-
amniotic and intraperitoneal gene transfer to fetal sheepin 100% of the animals. A miscarriage occurred in one
ewe carrying twin pregnancies despite a straightforward (9). In comparison, another study of xenotransplantation
of human cord blood and fetal bone marrow MSCs intoultrasound-guided amniocentesis procedure. This com-
pares favorably to the higher rates of fetal loss observed fetal sheep had an overall 37.5% fetal loss rate (33).
In our experimental setting, mesenchymal progeni-in other studies where different sources of autologous
MSCs were used for autologous in utero transplantation. tors were derived in 100% of the animals. In keeping
with previous studies in sheep (20) and other speciesIn particular, fetal transplantation of autologous MSCs
derived from fetal liver in sheep carried an overall mor- (16), the AFMSCs were maintained in feeder-free cul-
tures, had a doubling time of approximately 36–48 hours,tality rate of 73% (42). For IUSCT in fetal sheep, trans-
uterine ultrasound-guided injection has been shown to and displayed mesenchymal stem cell markers (CD44,
CD58, and CD166), while being negative for macro-achieve a higher rate of engraftment when compared to
an open delivery procedure at hysterotomy (70% vs. phages, hematopoietic, and endothelial markers (CD14,
CD31, and CD45). When cultured in conditional me-20%) (32), despite in both cases cells were delivered
intraperitoneally, commonly the route of delivery for fe- dium (48) these cells could differentiate into adipogenic
and osteogenic lineages. The potential of differentiationtal blood transfusion in clinical practice although less
commonly performed than cordocentesis (47). In our and characterization of all the surface markers did not
change even after viral transduction. After being trans-study, we did not observe any miscarriage related to the
transplantation procedure. Our miscarriage rate was sim- duced, expanded undifferentiated cells were autotrans-
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planted without sorting for two reasons. Firstly, we were served was admittedly low. However, for some congeni-
tal diseases, such as severe hemophilia, only 1% levelspleased by the relatively high level of gene transfer that
was achieved in the AFMSCs. Secondly we wished to of protein expression are required to ameliorate the se-
vere phenotype (50). Thus, for many congenital diseasesavoid clonal selection of the cells and to observe what
could happen with minimal manipulation. While we this may be sufficient to improve the phenotype or even
effect a cure (37).have previously shown that AFS cells can be efficiently
transduced using adenoviral vectors (22), lentivirus vec- The number of expanded transduced amniotic fluid
cells increased as the length of time available for celltors have the advantage of allowing sustained transgene
expression (36). We have shown that lentivirus vectors culture increased (Fig. 5A). Interestingly, however, there
was no evidence of a dose–response effect, since theare able to efficiently transduce sheep AFMSCs. This is
particularly relevant when considering that various pro- number of injected cells did not correlate with the num-
ber of organs containing transduced cells (Fig. 5B, C).genitors could be isolated from the amniotic fluid, and
have demonstrated the possibility to differentiate into Moreover, in some of the cases, the number of organs
in which the GFP protein was detected was higher thanmyocardium, lung epithelial cell, smooth muscle, and
neuron cells (3,15,24). More recently we have also re- the number of organs in which GFP DNA was detected.
It is likely that cells were generating a chimerism andported that ckit+/LIN− selected AF cells have hematopoi-
etic potential both in vitro and in vivo (18). As a conse- were not present in the entire organ. Since different sam-
ples of the same organs were analyzed for DNA andquence, autologous AF cells could be engineered and
used to engraft a fetus affected by a congenital disorder protein, it is possible that some samples did not contain
positive cells. Injected cells appeared to migrate mainlyin order to provide for expression of the damaged/defec-
tive gene. to the liver, heart, adrenal gland, and umbilical cord of
the fetus, and to extraembryonic tissues such as the am-The level of injected cells in fetal tissues that we ob-
Figure 5. The correlation between the number of injected cells and presence of GFP-positive cells in fetal organs, and evidence of
maternal spread of GFP-AFMSCs. There was a moderate correlation (r = 0.59) between the final cell number and days of cell
expansion in vitro (A). The correlation between the number of injected cells and the number of detectable GFP-positive organs did
not showed significance in PCR (r = −0.18) (B) and Western blot (r = −0.4) (C). The PCR gel (D) showed all maternal organs
analyzed, including adrenal gland, liver, lung, kidney, bone marrow (BM), and heart, were negative for GFP DNA detection. The
fetal liver was strong positive. P, positive control; N, negative control.
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Figure 6. Flow cytometric analysis for GFP expression in fetal blood, tissues, and maternal sam-
ples taken at postmortem examination. Histograms demonstrate positive GFP detection in the fetal
liver (1.22%) and fetal bone marrow (0.84%). Cells from a control untransduced fetal sheep were
used as negative control (light gray). Fetal cord blood, fetal spleen, maternal blood, and maternal
bone marrow were negative for migration. BM: bone marrow.
niotic membranes, placentomes, and amniotic fluid. of autologous MSCs achieved was not significantly dif-
ferent from that observed after allogeneic-derived MSCsCells delivered to the peritoneal cavity are likely to mi-
grate into the blood stream, from where they can travel (0.16% vs. 0.56%). However, engraftment in the fetal
liver was higher (0.65% vs. 0.23%) after autologous trans-to the placenta and membranes via the umbilical vein in
the cord. This study was performed in normal fetuses in plantation (42). Similarly, we observed a good number
of injected cells in the fetal liver, confirmed also by thewhich there is no engraftment advantage for the injected
cells. Different results may be obtained in animal mod- appearance of rare cells coexpressing GFP and CK18 or
AFP. Further studies need to be conducted to evaluate theels of disease where damaged organs may provide a
niche for injected cells to engraft. possibility that AFMSCs may engraft in the liver. This
could be particularly relevant since hepatocyte differentia-The question of whether autologous IUSCT is supe-
rior to allogeneic cells is as yet unresolved. In a previous tion may lead to the treatment of congenital metabolic
disorders (31,40). Our results could be improved by pre-study in sheep of fetal transplantation of MSC derived
from fetal liver, the level of bone marrow engraftment conditioning the cells in hepatocyte differentiation media
FACING PAGE
Figure 7. Immunofluorescence for GFP expression and markers of MSC differentiation. GFP-positive AFMSC migration and
differentiation was studied using GFP immunofluorescence and co-staining with tissue markers in fetal organs such as the liver
(CK18; A–G) and skeletal muscle and heart (laminin; H–I). In fetal liver, GFP-positive cells (green) mainly localized in the stroma
(A–D) and did not co-stain with CK18, a marker of hepatocytes stained red. In another section, however, a few rare cells co-
stained for GFP and CK-18 (E–G, indicated by the arrowhead). Some cells that only stained for GFP remained in the stroma (F,
indicated by the arrow). Histogram showed percentages of positive GFP cells with/without CK18 staining detected per high-power
field in the liver section (H). Error bar: SD. In sections of fetal skeletal muscle (I) and heart (J), GFP-positive cells did not co-
stain for laminin (red). Immunofluorescence of placental sections showed GFP-positive cells (K–M). Scale bars: 20 µm.
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Figure 8. Immunofluorescence for CK18 and AFP expression in fetal liver and amniotic fluid stem cells. Upper panel shows
positive CK18 expression in cells cultured from a control fetal sheep liver but no expression in amniotic fluid mesenchymal stem
cells (AFMSCs) or transduced cells (GFP-AFMSCs) before injection. An uninjected sheep fetus of comparable gestational age was
used as the control. The lower panel shows coexpression of GFP with expression of α-fetoprotein (AFP), another liver-specific
marker in the fetal liver after transplantation of transduced AFMSCs. Scale bars: 20 µm.
(41,52) and by injection in the umbilical vein (44). The markers does not fully address the ability of these cells
to generate functional hepatocytes.latter in particular might preferentially target the liver
when compared with the widespread tissue migration ob- In summary, this study demonstrates widespread and
systemic migration after fetal injection of transduced au-served after peritoneal injection in this study.
In addition, the interval between injection and sched- tologous AFMSCs in the sheep. We successfully cul-
tured sheep AFMSCs, and achieved a high level ofuled postmortem was relatively short. We cannot ex-
clude that differentiation may occur mainly (or only) by lentivirus vector-mediated gene transfer. Longer term
follow-up studies are needed to investigate whether cellcell fusion and further studies are needed, possibly in a
small animal model, to further investigate this aspect. engraftment is occurring. Our results, however, demon-
strate that this approach may hold promise for targetedMoreover, the cytoplasmic marker (i.e., GFP) in an au-
tologous model does not distinguish cell fusion from dif- treatment of severe early onset genetic diseases that can
be diagnosed in utero.ferentiation. Finally, even the expression of hepatocyte
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